


Application No.: 09/909,012

Docket No.: SCHERING 3.0-121

IN THE CLAIMS

(currently amended) A compound, including enantiomers, stereoisomers, rotamers and tautomers of said compound, and pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formula I:

Formula I

wherein:

G, J and Y may be the same or different and are independently selected from the group consisting of the moieties: H, alkyl, alkyl-aryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl, alkyloxy, alkyl-aryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkyl-aryl amino, arylamino, heteroaryl amino, cycloalkyl amino and heterocycloalkyl amino, with the proviso that Y maybe additionally optionally substituted with X^{11} or X^{12} ;

X^{11} is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl, aryl, alkylaryl, arylalkyl, heteroaryl, alkylheteroaryl, or heteroarylalkyl moiety, with the proviso that X^{11} may be additionally optionally substituted with X^{12} ;

X^{12} is hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, alkylsulfonamido, arylsulfonamido, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyloxy,

Application No.: 09/909,012

Docket No.: SCHERING 3.0-121

alkylureido, arylureido, halogen, cyano, or nitro, with the proviso that said alkyl, alkoxy, and aryl may be additionally optionally substituted with moieties independently selected from X^{12} .

R^1 is COR^5 or $B(OR)_2$, wherein R^5 is selected from the group consisting of CH , OR^8 , with the proviso that R^8 is not alkyl, NR^9R^{10} , CF_3 , C_2F_5 , C_3F_7 , CF_2R^6 , R^6 and COR^7 wherein R^7 is selected from the group consisting of H , OH , OR^8 , CHR^9R^{10} , and NR^9R^{10} , wherein R^6 , R^8 , R^9 and R^{10} may be the same or different and are independently selected from the group consisting of H , alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, cycloalkyl, arylalkyl, heteroarylalkyl, $CH(R^{1'})COOR^{11}$, $CH(R^{1'})CONR^{12}R^{13}$, $CH(R^{1'})CONHCH(R^{2'})COOR^{11}$, $CH(R^{1'})CONHCH(R^{2'})CONR^{12}R^{13}$, $CH(R^{1'})CONHCH(R^{2'})R'$, $CH(R^{1'})CONHCH(R^{2'})CONHCH(R^{3'})COOR^{11}$, $CH(R^{1'})CONHCH(R^{2'})CONHCH(R^{3'})CONR^{12}R^{13}$, $CH(R^{1'})CONHCH(R^{2'})CONHCH(R^{3'})CONHCH(R^{4'})COOR^{11}$, $CH(R^{1'})CONHCH(R^{2'})CONHCH(R^{3'})CONHCH(R^{4'})CONR^{12}R^{13}$, $CH(R^{1'})CONHCH(R^{2'})CONHCH(R^{3'})CONHCH(R^{4'})CONHCH(R^{5'})COOR^{11}$, and $CH(R^{1'})CONHCH(R^{2'})CONHCH(R^{3'})CONHCH(R^{4'})CONHCH(R^{5'})CONR^{12}R^{13}$, wherein $R^{1'}$, $R^{2'}$, $R^{3'}$, $R^{4'}$, $R^{5'}$, R^{11} , R^{12} , R^{13} , and R' may be the same or different and are independently selected from a group consisting of H , alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, alkyl-aryl, alkyl-heteroaryl, aryl-alkyl and heteroarylalkyl;

Z is selected from O , N , or CH ;

W maybe present or absent, and if W is present, W is selected from $C=O$, $C=S$, or SO_2 ; and

Application No.: 09/909,012

Docket No.: SCHERING 3.0-121

R , R^1 , R^2 , R^3 and R^4 are independently selected from the group consisting of H; C1-C10 alkyl; C2-C10 alkenyl; C3-C8 cycloalkyl; C3-C8 heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro; oxygen, nitrogen, sulfur, or phosphorus atoms (with said oxygen, nitrogen, sulfur, or phosphorus atoms numbering zero to six); (cycloalkyl)alkyl and (heterocycloalkyl)alkyl, wherein said cycloalkyl is made of three to eight carbon atoms, and zero to six oxygen, nitrogen, sulfur, or phosphorus atoms, and said alkyl is of one to six carbon atoms; aryl; heteroaryl; alkyl-aryl; and alkyl-heteroaryl;

wherein said alkyl, heteroalkyl, alkenyl, heteroalkenyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties may be optionally substituted, with said term "substituted" referring to optional and chemically-suitable substitution with one or more moieties selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, heterocyclic, halogen, hydroxy, thio, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, sulfonamide, sulfoxide, sulfone, sulfonylurea, hydrazide, and hydroxamate; with the proviso that R^2 is not arylalkyl or cyclohexylalkyl.

2. (previously presented) The compound of claim 1 wherein R^1 is $COOR^5$, and R^5 is OH, $COOR^8$ or $CONR^9R^{10}$.

3. (previously presented) The compound of claim 2, wherein R^1 is $COCONR^9R^{10}$, and R^9 is H, R^{10} is selected from the group consisting of H, $CH(R^{1'})COOR^{11}$, $CH(R^{1'})CONR^{12}R^{13}$, $CH(R^{1'})CONHCH(R^{2'})COOR^{11}$, $CH(R^{1'})CONHCH(R^{2'})CONR^{12}R^{13}$, and $CH(R^{1'})CONHCH(R^{2'})(R')$.

Application No.: 09/909,012

Docket No.: SCHERING 3.0-121

4. (original) The compound of claim 3, wherein R^{10} is $CH(R^{1'})CONHCH(R^{2'})COOR^{11}$, $CH(R^{1'})CONHCH(R^{2'})CONR^{12}R^{13}$, or $CH(R^{1'})CONHCH(R^{2'})(R')$, wherein $R^{1'}$ is H or alkyl, heteroalkyl and $R^{2'}$ is phenyl, substituted phenyl, hetero atom-substituted phenyl, thiophenyl, cycloalkyl, piperidyl and pyridyl.


5. (original) The compound of claim 4, wherein $R^{1'}$ is H.

6. (original) The compound of claim 5, wherein

R^{11} is H or tert-butyl;

R' is hydroxymethyl; and

$R^{2'}$ is selected from the group consisting of:



wherein:

U^1 and U^2 maybe same or different and are independently selected from the group consisting of H, F, CH_2COOH , CH_2COOMe , CH_2CONH_2 , $CH_2CONHMe$, CH_2CONMe_2 , azido, amino, hydroxyl, substituted amino, substituted hydroxyl;

U^3 and U^4 maybe same or different and are O or S;


U^5 is selected from the moieties consisting of alkylsulfonyl, aryl sulfonyl, heteroalkyl sulfonyl, heteroaryl sulfonyl, alkyl carbonyl, aryl carbonyl, heteroalkyl carbonyl, heterocaryl carbonyl, alkoxycarbonyl, aryloxycarbonyl,

Application No.: 09/909,012

Docket No.: SCHERING 3.0-121

heteroaryloxy carbonyl, alkylaminocarbonyl, arylaminocarbonyl and heteroarylamino carbonyl or combinations thereof; and $R^{12}R^{13}$ is selected from the group consisting of:


NH_2 , $NHMe$, $N(Me)OMe$, NMe_2 .



wherein U^6 is H, OH, or CH_2OH .



























7. (original) The compound of claim 2, wherein R^2 is selected from the group consisting of the following moieties:

Docket No.: SCHERING 3.0-121



Application No.: 09/909,012


Docket No.: SCHERING 3.0-121



and


Application No.: 09/909,012

Docket No.: SCHERING 3.0-121




wherein $R^{31} = \text{OH}$ or O-alkyl;

γ^{19} is selected from the following moieties:















and γ^{20} is selected from the following moieties:



9. (original) The compound of claim 8, wherein R^3 is selected from the following structures:

Application No.: 09/909,012


























Docket No.: SCHERING 3.0-121



10. (original) The compound of claim 9, wherein $Z = N$ and $R^4 =$
- h.
11. (original) A compound of claim 10, wherein W is $C=O$, or SO_2 .
12. (original) A compound of claim 11, wherein Y is selected from the following moieties:



































Application No.: C9/909,012

Docket No.: SCHERING 3.0-121




Application No.: 09/909,012

Docket No.: SCHERING 3.0-121



Application No.: 09/909,012

Docket No.: SCHERING 3.0-121



Application No.: 09/909,012

Docket No.: SCHERING 3.0-121

Y^{15} and Y^{16} may be the same or different and are independently selected from alkyl, aryl or heteroalkyl, or heteroaryl;


Y^{17} is CF_3 , NO_2 , $CONH_2$, OH , $COOCH_3$, OCH_3 , OC_6H_5 , C_6H_5 , COC_6H_5 , NH_2 , or $COOH$; and

Y^{18} is $COOCH_3$, NO_2 , $N(CH_3)_2$, F , OCH_3 , CH_2COOH , $COOH$, SO_2NH_2 , or $NHCOCH_3$.

13. (original) A compound of claim 12, wherein Y is selected from the group consisting of:

Application No.: 09/909,012

Docket No.: SCHERING 3.0-121




wherein:

 $Y^{17} = CF_3, NO_2, CONH_2, OH, NH_2, \text{ or } COOH;$ $Y^{18} = F, COOH.$

Application No.: 09/909,012

Docket No.: SCHERING 3.0-121

14. (original) The compound of claim 13, wherein J is selected from the group consisting of:




15. (original) The compound of claim 14 where in J is H, CH₃ or Bn.

16. (original) The compound of claim 15 wherein G is selected from moieties:


Application No.: 09/909,012

Docket No.: SCHERING 3.0-121















Application No.: 09/909,012

Docket No.: SCHERING 3.0-121





















Q=



17. (original) The compound of claim 16, wherein G is selected from the group consisting of :

Application No.: 09/909,012

Docket No.: SCHERING 3.0-121









18. (original) A pharmaceutical composition comprising as an active ingredient a compound of claim 1.
19. (previously presented) The pharmaceutical composition of claim 18 suitable for use in treating disorders associated with Hepatitis C virus.
20. (original) The pharmaceutical composition of claim 18 additionally comprising a pharmaceutically acceptable carrier.
21. (canceled)
22. (canceled)
23. (canceled)
24. (canceled)
25. (previously presented) A compound exhibiting hepatitis C virus (HCV) protease inhibitory activity, including enantiomers, stereoisomers, rotamers and tautomers of said compound, and pharmaceutically acceptable salts or solvates of said compound,

Application No.: 09/909,012


Docket No.: SCHERING 3.0-121

said compound being selected from the group of compounds with structures listed below:




Application No.: 09/909,012

Docket No.: SCHERING 3.0-121



R = Me


R = Benzyl

X = O^tBu


X = OH

X = NH₂

X = NMeOMe


X = NMe₂X = O^tBu

X = OH




Application No.: 09/909,012




Docket No.: SCHERING 3.0-121




X = H, Y = tBu; X = tBu, Y = H



R = Propargyl; R = Allyl

X = O^tBu; X = OHX = O^tButyl

X = OH




Application No.: 09/909,012


Docket No.: SCHERING 3.0-121

X = O^tButyl

X = OH


X = NMe₂X = O^tBu

X = OH

R = ^tBu


R = H

R = Me




X = H, Y = COOH

X = COOH, Y = H



Application No.: 09/909,012

Docket No.: SCHERING 3.0-121



26. (previously presented) A pharmaceutical composition for treating disorders associated with the hepatitis C virus (HCV) protease, said composition comprising therapeutically effective amount of one or more compounds in claim 25 and a pharmaceutically acceptable carrier.

27. (original) The pharmaceutical composition of claim 26, additionally containing an antiviral agent.











28. (previously presented) The pharmaceutical composition of claim 26 or claim 27, further containing an interferon.

29. (original) The pharmaceutical composition of claim 28, wherein said antiviral agent is ribavirin and said interferon is α -interferon.

Application No.: 09/909,012




Docket No.: SCHERING 3.0-121

30. (previously presented) A compound selected from the group consisting of:




Application No.: 09/909,012

Docket No.: SCHERING 3.0-121



and



Application No.: 09/909,012

Docket No.: SCHERING 3.0-121

or an enantiomer, stereoisomer, rotamer or tautomer thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound exhibits hepatitis C virus (HCV) inhibitory activity.

31. (original) A pharmaceutical composition, comprising one or more compounds of claim 30.

32. (canceled)

33. (canceled)

34. (canceled)

35. (canceled)

36. (canceled)

37. (canceled)

38. (original) The compound of claim 7, wherein R^3 is cyclohexyl.

39. (original) The compound of claim 11, wherein Y is selected from the group consisting of 2-carboxy-3-hydroxyphenyl, 3-tetrahydrofurylmethoxy, and 2-sulfophenyl.

40. (original) The compound of claim 15, wherein G is selected from the group consisting of ethylsulfonylmethyl, phenylsulfonylmethyl, 2-phenylethylsulfonylmethyl and 1-naphthylsulfonylmethyl.